NPDRNon-Proliferative Diabetic Retinopathy
NPDRNuclear Preliminary Design Review
References in periodicals archive ?
We studied 50 patients with PDR, 50 patients with NPDR and 50 healthy controls.
Based on the Schirmer I test results, 60% of PDR patients and 46% of NPDR patients had dry eye syndrome.
The prevalence was 68% in diabetic patients with PDR, 18% in diabetic patients with NPDR and 4% in the control group.
This study had no control group, but the prevalence of dry eye syndrome in NPDR patients was higher than our study that may be due to type of tests which used in the diagnosis of dry eye syndrome (Schirmer test, TBUT test and Fluorescein Staining of the Cornea) [14].
Prevalence of syndrome between PDR and NPDR with control group has not been compared previously which were compared in our study.
Its prevalence in patients with NPDR had no significant difference with PDR and control groups that maybe due to the low sample size or better control diabetes in NPDR.
We estimated the transition probability from mild or moderate NPDR (35, 43) to vision-threatening states using UKPDS functions of disease severity, diabetes duration, and 14-year average of patient HbA1c (Stevens, Stratton, and Holman 2002).
Patients diagnosed with mild NPDR or more severe states received the treatment recommended by AAO's Preferred Practice Patterns (American Academy of Ophthalmology Retina Panel 2008): one to four annual ophthalmoscopic evaluations, fluorescein angiography with focal/grid laser photocoagulation treatment for CSME, and scatter (panretinal) laser photocoagulation therapy for Non-HR or HR-PDR and no CSME.